Why Talk With Your Healthcare Provider About Your HIV-Related Excess Abdominal Fat?
Because if it’s bothering you, it’s worth talking about.
And because there’s EGRIFTA® (tesamorelin for injection). The first FDA-approved medicine shown to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. The excess abdominal fat is called visceral adipose tissue (VAT).
EGRIFTA® is an injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA® contains a growth hormone-releasing factor (GRF).
- The impact and safety of EGRIFTA® on cardiovascular health has not been studied.
- EGRIFTA® is not indicated for weight loss management.
- It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.
- It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.
Ask your healthcare provider for more information about EGRIFTA®. To get the discussion started with your healthcare provider, download this guide about HIV-related Excess Abdominal Fat. If you have been prescribed EGRIFTA® and have questions about product support, please call Egrifta Assist ™ toll-free at 1-844-EGRIFTA (347-4382).
You are encouraged to report negative side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This information is not intended to replace discussions with your doctor. For additional information about EGRIFTA®, please consult the
Prescribing Information, Patient Information, and Patient Instructions for Use,
and talk to your doctor. You can also call toll-free 1-844-EGRIFTA (347-4382). EGRIFTA® is available by prescription only.